Abstract 1235
Background
Uveal Melanoma (UVM) is the most common ocular malignancy. Many mutations were identified in affected patients defining genetic predisposition syndromes. Previous studies discussed separately the incidence of single or second primary ocular melanomas. However, understanding the genetic background, and relation to other tumors requires further investigation for defining the UVM subgroups, their shared developmental and, hence, the targeting mechanisms.
Methods
We used Surveillance Epidemiology and End Results program of the National Cancer Institute, United States, to review patients diagnosed with UVM, either as single primary or combined with other malignancies, between 1973 and 2015. We have calculated standardized incidence ratios (SIR) and measured risk in the form of Observed/Expected ratios (O/E) and Hazard Ratios (HR).
Results
We have identified 7,386 patients diagnosed with single primary UVM, besides 646 with UVM followed by another malignancy and 437 patients diagnosed with a primary UVM after other malignancies. SIR of developing another malignancy following UVM was significant and increased most within the first 5 years following UVM following choroid uveal melanoma (1.198, 95%CI=1.056-1.353). The risk of developing melanomas of the skin, thyroid cancers, and kidney cancers, increased significantly within the first 5 years following UVM, with SIRs (3.763, 95%CI=2.539-5.372), (3.158, 95%CI=1.270-6.506), and (2.618, 95%CI=1.465-4.317), respectively. SIR of developing a second UVM following another malignancy was significant between the 5th and 10th years following the first cancer diagnosis (O/E=1.204, 95% CI = 1.007-1.428), where the increase of UVM risk was highest among patients with primary prostate cancer (1.404, 95%CI=1.024-1.878) or leukemia (2.915, 95%CI=1.070-6.345). Cox models did not show a significant difference between the overall survival of single UVM and second UVM, but females showed better overall survival outcomes. In addition, Ciliary body tumors, and dark-skinned people were associated with worse survival outcomes.
Conclusions
The three groups of uveal melanoma showed different behaviors that may represent diverse underlying developmental mechanisms.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5031 - Sarcoidosis-Like Reaction Mimics Progression in patients treated with immune checkpoint inhibitors
Presenter: Sophie Hans
Session: Poster Display session 3
Resources:
Abstract
5650 - Tissue-based activation of mucosal-associated invariant T (MAIT) cells in combination ipilimumab and nivolumab checkpoint inhibitor (CI) colitis.
Presenter: Sarah Sasson
Session: Poster Display session 3
Resources:
Abstract
5944 - Significance of severe immune-related adverse effects (irAE) on patients with advanced tumors treated with immune checkpoint inhibitors being admitted for secondary toxicity: Clinical relevance and next steps
Presenter: Leyre Zubiri
Session: Poster Display session 3
Resources:
Abstract
5989 - Implementation of a dedicated immuno-oncology toxicity service reduces the acute impact of immune-related adverse events
Presenter: Anna Olsson-Brown
Session: Poster Display session 3
Resources:
Abstract
3267 - Cardiotoxic and pro-inflammatory effects induced by the association of immune checkpoint inhibitor Pembrolizumab and Trastuzumab in preclinical models
Presenter: Nicola Maurea
Session: Poster Display session 3
Resources:
Abstract
3417 - Interstitial lung disease associated with immune-checkpoint inhibitors in malignant diseases
Presenter: Akira Yamagata
Session: Poster Display session 3
Resources:
Abstract
2071 - A Phase 1 Study of Intraperitoneal MCY-M11 Anti-Mesothelin CAR for Women with Platinum Resistant High Grade Serous Adenocarcinoma of the Ovary, Primary Peritoneum, or Fallopian Tube, or Subjects with Peritoneal Mesothelioma with Recurrence after Prior Chemotherapy
Presenter: Christina Annunziata
Session: Poster Display session 3
Resources:
Abstract
4935 - Trial in progress: First-in-human study of a novel anti-NY-ESO-1–anti-CD3, TCR-based bispecific (IMCnyeso) as monotherapy in NY-ESO-1/LAGE-1A-positive advanced solid tumors (IMCnyeso-101)
Presenter: Juanita Lopez
Session: Poster Display session 3
Resources:
Abstract
5613 - Nimotuzumab-Cisplatin-Radiation versus Cisplatin-Radiation in HPV negative oropharyngeal cancer
Presenter: Kumar Prabhash
Session: Poster Display session 3
Resources:
Abstract
2576 - Interim analysis of a single arm phase 2 study of adjuvant nivolumab after salvage resection in head and neck squamous cell carcinoma patients previously treated with definitive therapy.
Presenter: Trisha Wise-draper
Session: Poster Display session 3
Resources:
Abstract